Onyx's higher marketing expenses for Kyprolis seen as money well spent
This article was originally published in Scrip
Onyx Pharmaceuticals won't offer sales projections for its multiple myeloma drug Kyprolis (carfilzomib), which won accelerated US FDA approval on 20 July for patients who failed treatment with at least two prior therapies (scripintelligence.com, 23 July 2012), but stock analysts offered their own opinions on the drug's value after the firm announced its second quarter 2012 financial results.
You may also be interested in...
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.